Most patients assume an eye injection is a one-time fix. It’s not — and the cost reality of anti-VEGF therapy is one of the most important things you can understand before starting treatment. Injections for wet macular degeneration, diabetic macular edema, or retinal vein occlusion typically happen every 4–12 weeks, indefinitely. At $200–$2,000 per dose depending on the drug, the annual tab can easily hit $10,000–$24,000 before insurance adjustments.
Here’s the actual pricing landscape.
Drug-by-Drug Cost Breakdown
Four anti-VEGF drugs dominate the US market. Their clinical efficacy is broadly comparable for most conditions — but their prices are not. The choice of drug often comes down to your insurance formulary, your retinal specialist’s preference, and your financial situation.
| Drug | Wholesale Cost Per Dose | Typical Patient OOP (w/ insurance) | Common Use |
|---|---|---|---|
| Bevacizumab (Avastin, off-label) | $50–$200 | $0–$50 | Wet AMD, DME, RVO |
| Ranibizumab (Lucentis) | $1,800–$2,000 | $0–$300 | Wet AMD, DME, RVO, ROP |
| Aflibercept (Eylea) | $1,800–$2,100 | $0–$300 | Wet AMD, DME, RVO |
| Faricimab (Vabysmo) | $2,100–$2,400 | $0–$400 | Wet AMD, DME |
| Brolucizumab (Beovu) | $1,800–$2,000 | $0–$300 | Wet AMD |
Avastin is the financial outlier. It’s a cancer drug used off-label in ophthalmology at a fraction of the cost of the branded anti-VEGF agents. The NEI-funded CATT trial established that Avastin and Lucentis produce statistically equivalent visual outcomes for wet AMD. Many retinal specialists use Avastin as first-line treatment; others are required by practice or insurance policy to start with branded drugs. It’s worth asking.
The Real Annual Cost
A 2024 analysis published in Ophthalmology estimated the average US patient with wet AMD receives 7–9 injections per year. Run that math on different drugs:
- Avastin at 8 injections: ~$800–$1,600/year wholesale (patient pays very little)
- Eylea at 8 injections: ~$14,400–$16,800/year wholesale
- Faricimab at 6 injections (longer dosing intervals): ~$12,600–$14,400/year
Insurance covers the bulk of this for most Medicare and commercially insured patients, but the 20% coinsurance under Medicare Part B can still add up to $2,000–$4,000 per year on branded drugs.
Medicare Part B covers intravitreal injections at 80% after the Part B deductible because they’re administered in a physician’s office. That 20% coinsurance applies to the drug’s ASP (Average Sales Price) plus a 6% add-on. For Eylea at $2,100 per dose, your 20% share is ~$420/dose — potentially $3,000+ per year if you’re injecting every 6–8 weeks. A Medigap supplement policy often covers this 20%, making it worth calculating carefully.
What You’ll Also Pay For
The drug cost is just one line on your bill. Each injection visit includes:
Office visit/procedure fee: $150–$400 depending on the practice and whether a separate exam is performed. This is billed with a procedure code for the injection plus an E&M code if examination is documented.
OCT imaging: Most retinal specialists perform optical coherence tomography at every injection visit to assess fluid and treatment response. Budget $150–$350 per scan without insurance, or a $25–$75 copay with it.
Fluorescein angiography (periodic): Less frequent — usually at diagnosis and when disease changes — but adds $400–$800 per session.
The AAO estimates that approximately 2 million Americans have wet AMD requiring treatment, making anti-VEGF one of the highest-volume injection procedures in medicine. That volume has driven some price competition and newer biosimilar entrants.
Biosimilars Are Changing the Market
FDA-approved ranibizumab biosimilars (including Cimerli and Byooviz) entered the US market in 2023 at 40–60% lower cost than branded Lucentis. Aflibercept (Eylea) biosimilars followed in 2024–2025. These compounds are clinically equivalent to their reference drugs by FDA definition.
If you’re currently on a branded agent and cost is a concern, ask your retinal specialist whether a biosimilar is appropriate for your condition. Some insurers now require biosimilar step therapy before covering branded biologics.
Never skip or delay injections to manage cost without talking to your doctor first. For conditions like wet AMD, a single skipped injection can result in irreversible vision loss — sometimes within weeks. If cost is a barrier, ask about manufacturer patient assistance programs, the National Eye Institute’s resource line, or whether Avastin is medically appropriate for your case.
Reducing Your Out-of-Pocket Costs
Manufacturer copay programs: Regeneron (Eylea) and Genentech (Lucentis, Vabysmo) both offer copay assistance for commercially insured patients. Eligible patients often pay $0 per injection.
State pharmaceutical assistance programs: Many states have SPAP programs that layer on top of Medicare to reduce the 20% coinsurance burden.
Compounding pharmacies: Avastin used in ophthalmology is typically prepared by a compounding pharmacy — your retinal practice handles this directly. You’re not sourcing the drug yourself.
Clinical trials: Patients enrolled in retinal trials at academic medical centers often receive anti-VEGF treatment at no cost. ClinicalTrials.gov lists active enrollment opportunities.
The bottom line: with good insurance and assistance programs, most patients pay very little per injection. Without coverage, the cost is substantial — but not unavoidable.